Literature DB >> 26261652

Distant dissemination of mixed low-grade astroblastoma-arteriovenous malformation after initial operation: a case report.

Kun Yao1, Bin Wu2, Mei Xi3, Zejun Duan1, Jiqiang Wang2, Xueling Qi1.   

Abstract

We present a rare case of low-grade astroblastoma coexisting with an arteriovenous malformation (AVM) underwent surgery two times in a 38-year-old man. After the first surgery, this case was reported as a mixed low-grade astroblastoma and AVM. The lesion was completely resected surgically along with AVM. The patient underwent postoperative radiotherapy. Twenty months later, MRI showed enhanced lesions in suprasellar, pineal region and multiple small lesions in the spinal cord, whereas completely no recurrent lesion at the primary tumor site. So, the patient rationally underwent surgical removal in suprasellar and pineal region. After the second surgery, this case was diagnosed as a high-grade astroblastoma. Cells from the second surgical specimens showed high MIB-1 index and an increased olig-2 index. In addition, it is not common for low-grade astroblastoma metastasis to suprasellar, pineal region and spine with completely no recurrence at the original primary tumor site. Therefore it is difficult to predict tumor behavior and patient's clinical outcome merely based on histologic features. The important issue is whether the AVM was thought to be the cause of poor progress of this tumor. More cases are needed to confirm this. Classification and histogenesis of this tumor is still debated. Lack of clinicopathological correlation makes the prognosis of this tumor unpredictable. Anyway, we should be very discreet to treat the astroblastoma, even for low-grade astroblastoma.

Entities:  

Keywords:  Arteriovenous malformation; astroblastoma; dissemination; prognosis; treatment

Mesh:

Year:  2015        PMID: 26261652      PMCID: PMC4525986     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  16 in total

Review 1.  Cerebral arteriovenous malformations. Part 1: cellular and molecular biology.

Authors:  Parham Moftakhar; Jason S Hauptman; Dennis Malkasian; Neil A Martin
Journal:  Neurosurg Focus       Date:  2009-05       Impact factor: 4.047

2.  Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization.

Authors:  D J Brat; Y Hirose; K J Cohen; B G Feuerstein; P C Burger
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

3.  High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis.

Authors:  Marija Balic; Martin Pichler; Jasmin Strutz; Ellen Heitzer; Christoph Ausch; Hellmut Samonigg; Richard J Cote; Nadia Dandachi
Journal:  J Mol Diagn       Date:  2009-01-29       Impact factor: 5.568

4.  The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages.

Authors:  Hirohide Takebayashi; Yoko Nabeshima; Shosei Yoshida; Osamu Chisaka; Kazuhiro Ikenaka; Yo-ichi Nabeshima
Journal:  Curr Biol       Date:  2002-07-09       Impact factor: 10.834

Review 5.  Cerebral astroblastoma: analysis of six cases and critical review of treatment options.

Authors:  Maurizio Salvati; Alessandro D'Elia; Christian Brogna; Alessandro Frati; Manila Antonelli; Felice Giangaspero; Antonino Raco; Antonio Santoro; Roberto Delfini
Journal:  J Neurooncol       Date:  2009-02-13       Impact factor: 4.130

6.  Astroblastoma: does histology predict biologic behavior?

Authors:  B Thiessen; J Finlay; R Kulkarni; M K Rosenblum
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

7.  MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

Authors:  J Sadones; A Michotte; P Veld; C Chaskis; R Sciot; J Menten; E J R Joossens; T Strauven; L A D'Hondt; D Sartenaer; S F E H Califice; K Bierau; C Svensson; J De Grève; B Neyns
Journal:  Eur J Cancer       Date:  2008-10-20       Impact factor: 9.162

Review 8.  Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.

Authors:  Ping Zhan; Jing Wang; Xiao-jing Lv; Qin Wang; Li-xin Qiu; Xin-qing Lin; Li-ke Yu; Yong Song
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

9.  Cerebral astroblastoma.

Authors:  E Caroli; M Salvati; V Esposito; E R Orlando; F Giangaspero
Journal:  Acta Neurochir (Wien)       Date:  2004-04-13       Impact factor: 2.216

10.  Nuclear export of OLIG2 in neural stem cells is essential for ciliary neurotrophic factor-induced astrocyte differentiation.

Authors:  Takao Setoguchi; Toru Kondo
Journal:  J Cell Biol       Date:  2004-09-27       Impact factor: 10.539

View more
  5 in total

1.  Patterns of care and survival outcomes in patients with astroblastoma: an individual patient data analysis of 152 cases.

Authors:  Supriya Mallick; Rony Benson; Bhanuprasad Venkatesulu; Wineeta Melgandi; Goura K Rath
Journal:  Childs Nerv Syst       Date:  2017-05-05       Impact factor: 1.475

2.  Spinal astroblastoma: a rare tumour in an unusual location.

Authors:  Shilpa Rao; T A Nufina; Harsha Sugur; Kirit Arumalla; B Indira Devi; Vani Santosh
Journal:  Childs Nerv Syst       Date:  2022-02-12       Impact factor: 1.532

3.  A case of astroblastoma: Radiological and histopathological characteristics and a review of current treatment options.

Authors:  Derek C Samples; James Henry; Fang Frank Yu; Carlos Bazan; Izabela Tarasiewicz
Journal:  Surg Neurol Int       Date:  2016-12-12

Review 4.  Astroblastoma - a rare and challenging tumor: a case report and review of the literature.

Authors:  Nawal Hammas; Nadia Senhaji; My Youssef Alaoui Lamrani; Sanae Bennis; Elfaiz Mohamed Chaoui; Hind El Fatemi; Laila Chbani
Journal:  J Med Case Rep       Date:  2018-04-21

5.  IDH-1R132H mutation status in diffuse glioma patients: implications for classification.

Authors:  Peng-Fei Wang; Ning Liu; Hong-Wang Song; Kun Yao; Tao Jiang; Shou-Wei Li; Chang-Xiang Yan
Journal:  Oncotarget       Date:  2016-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.